Skip to main content

What the FDA labels say about taking them together

Lovastatin and ticagrelor

Ticagrelor's FDA label of May 7, 2026 names lovastatin in its drug interactions section; the lovastatin label PlainMeds reads does not name ticagrelor. The ticagrelor label: “Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects.”

Check it at the source: the lovastatin FDA label on DailyMed (effective May 6, 2026, Lupin Pharmaceuticals, Inc.); the ticagrelor FDA label on DailyMed (effective May 7, 2026, AstraZeneca Pharmaceuticals LP).

What does the lovastatin label say about ticagrelor?

Lovastatin's label (effective May 6, 2026) does not name ticagrelor in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Lovastatin), Lupin Pharmaceuticals, Inc., effective May 6, 2026 (SPL set df7ddf4f-d569-431e-81f1-9129d7043150), via openFDA; the full label on DailyMed

What does the ticagrelor label say about lovastatin?

Ticagrelor label, drug interactions

Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects.

Source: FDA drug label (BRILINTA), AstraZeneca Pharmaceuticals LP, effective May 7, 2026 (SPL set f7b3f443-e83d-4bf2-0e96-023448fed9a8), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

19Lovastatin generic labelers
28Ticagrelor generic labelers
LovastatinTicagrelor
Labeled forHigh cholesterol, Heart attack and coronary artery diseaseHeart attack and coronary artery disease, Stroke prevention
Boxed warningNoYes
Pharmacy cost (NADAC)$0.0436 per tablet 20 mg tablet$0.253 per tablet 90 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?